BMC Cancer (Dec 2019)

Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis

  • Alexandre André Balieiro Anastácio da Costa,
  • Elizabeth Santana dos Santos,
  • Deborah Porto Cotrim,
  • Natasha Carvalho Pandolfi,
  • Marcelle Goldner Cesca,
  • Henrique Mantoan,
  • Solange Moraes Sanches,
  • Adriana Regina Gonçalves Ribeiro,
  • Louise de Brot,
  • Graziele Bonvolim,
  • Paulo Issamu Sanematsu,
  • Ronaldo Pereira de Souza,
  • Joyce Maria Lisboa Maya,
  • Fabrício de Souza Castro,
  • João Paulo da Nogueira Silveira Lima,
  • Michael Jenwel Chen,
  • Andrea Paiva Gadelha Guimarães,
  • Glauco Baiocchi

DOI
https://doi.org/10.1186/s12885-019-6382-x
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Brain metastasis (BM) is a rare event in ovarian cancer patients. The current prognostic scores that have been used for other tumors do not account for specific characteristics of ovarian cancer, such as platinum sensitivity. Methods This retrospective cohort study examined patients with ovarian carcinoma and BM who were treated at a single institution from January 2007 to December 2017. Clinical data on the diagnosis of BM and follow-up were collected. Cox regression was used to evaluate prognostic factors for overall survival (OS). Results Of 560 patients, 26 presented with BM. Eight patients were treated with surgery, 15 with whole-brain radiotherapy (RT), and 5 with stereotactic RT, and 4 patients received systemic treatment at the diagnosis of BM. The median OS was 10.8 months. The following factors were associated with OS: platinum-sensitive recurrence (HR 0.34, 95% CI 0.12–0.99; p = 0.049), higher number of previous treatment lines (HR 1.57, 95% CI 1.12–2.19; p = 0.008), ECOG performance status (HR 2.52, 95% CI 1.24–5.09; p = 0.010), and longer interval from initial diagnosis to BM (p = 0.025). Notably, the number of brain metastasis, the largest tumor size, and progression outside of the CNS were not related to survival. Platinum sensitivity was not associated with any of the classic prognostic factors in brain metastasis patients such as number or size of brain metastasis or disease progression outside the CNS strengthening the hypothesis of the importance of platinum sensitivity to the prognosis of ovarian cancer patients with BM. Conclusions The factors related to the biological behavior of the ovarian cancer such as platinum sensitivity at the time of BM diagnosis, fewer number of previous treatment lines and interval from initial diagnosis were associated with survival in ovarian cancer patients with BM, while factors that are usually related to survival in BM in other cancers were not associated with survival in this cohort of ovarian cancer patients. The small number of patients did not allow us to exclude the prognostic role of these former factors that were not associated with survival in the present cohort.

Keywords